WuXi XDC Named Best CDMO Winner at 2024 World ADC Awards
SHANGHAI and SAN DIEGO, Nov. 8, 2024 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC" or the "Company", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in antibody-drug conjugates (ADCs) and other bioconjugates (XDCs), is proud to announce that it has been named the winner of the "Best CDMO" at the World ADC...
InxMed Presents Data regarding Potential Novel Way to Improve Therapeutic Window of ADC by Ifebemtinib and FIC ADC at 15th Annual World ADC
NANJING, China, Nov. 8, 2024 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company developing innovative therapies against tumor-treatment resistance and metastasis, is presenting preclinical data at 15th Annual World ADC Conference in San Diego regarding ifebemtinib (ifebe, IN10018), a highly potent and selective oral inhibitor of focal adhesion kinase (FAK), to enhance efficacy and improve safety of ADCs, and IN30758, a First-in-class ADC...
Ping An Health and Medtronic Form Strategic Partnership at the China International Import Expo (CIIE)
HONG KONG and SHANGHAI, Nov. 8, 2024 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor", "Ping An Health", or "the Company", Stock Code: 1833.HK) established a strategic partnership with Medtronic (Shanghai) Management Co., Ltd. ("Medtronic") at the 7th China International Import Expo (CIIE) held at the National Exhibition and Convention Center (Shanghai) on 6 November, 2024....
Shanghai thriving as global investment hub
BEIJING, Nov. 8, 2024 /PRNewswire/ -- A news report from chinadaily.com.cn： The 2024 Shanghai City Investment Promotion Conference, held on Nov 6, serves as a window for global businesses to explore Shanghai's evolving business environment and investment opportunities. The event, part of the 2024 China International Import Expo at the National Exhibition and Convention Center (Shanghai), is attended by representatives...
Akeso Published Mechanism of Action for CLDN18.2/CD47 Bispecific Antibody AK132 for the First Time at SITC Annual Meeting
HONG KONG, Nov. 8, 2024 /PRNewswire/ -- At the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024), held in Houston, USA, from November 6 - 10, Akeso Biopharma (9926. HK) presented the mechanism of action (MOA) research findings of its innovative bispecific antibody, AK132, targeting both Claudin18.2 (CLDN18.2) and CD47. AK132 is an asymmetric bispecific...
What to see at the 7th China International Import Expo
SHANGHAI, Nov. 7, 2024 /PRNewswire/ -- A news report from english.shanghai.gov.cn Scan the QR code to learn more about the exhibition highlights of the 7th China International Import Expo. Country Exhibition As a key highlight of the China International Import Expo, the Country Exhibition brings together 77 participating countries and international organizations. Notably, seven countries – Benin,...
United Imaging Receives First Approval in Canada
The uMI Panorama™ is being readied for sale in Canada and will ship from the company's Houston-based North American headquarters. HOUSTON, Nov. 7, 2024 /PRNewswire/ -- United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, has received Health Canada approval for multiple digital PET/CT models in the uMI Panorama product family. Jeffrey M. Bundy,...
Cancer Genetic Risk Assessment Guidelines Expand to Meet Growing Understanding of Hereditary Risk
National Comprehensive Cancer Network overhauls two major resources to help cancer care providers and other stakeholders stay current on cutting edge research into genetic/familial high-risk assessment. PLYMOUTH MEETING, Pa., Nov. 7, 2024 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers focusing on maintaining evidence-based expert consensus driven...
New Meta-Analysis Strengthens Evidence That Nuts May Lower Cardiovascular Risk
BARCELONA, Spain, Nov. 7, 2024 /PRNewswire/ -- A recent systematic review and meta-analysis funded by the International Nut and Dried Fruit Council (INC) has just been published in the prestigious scientific journal Nutrition, Metabolism and Cardiovascular Diseases. The study showed that current evidence provides a good indication that consuming nuts may advantageously affect...
Ascletis Announces Promising Results from a Phase I Study in Australia for First-in-Class Muscle-Preserving Weight Loss Drug Candidate ASC47 for the Treatment of Obesity
Data from a Phase I single ascending dose (SAD) study in Australia in subjects with elevated low-density lipoprotein cholesterol (LDL-C) showed that ASC47, via subcutaneous (SQ) injection, demonstrated a half-life of 21 days, supporting once-monthly administration in patients with obesity In multiple pre-clinical studies using the diet-induced obese (DIO) mouse model, ASC47 demonstrated healthy weight loss (muscle-preserving weight...
